2.39
Tharimmune Inc Aktie (THAR) Neueste Nachrichten
Tharimmune Appoints Jacob Asbury as Chief Financial Officer - citybiz
Tharimmune Appoints Jacob Asbury as New CFO - TipRanks
Tharimmune appoints Jacob Asbury as chief financial officer - Investing.com
Tharimmune (NASDAQ: THAR) appoints ex‑Clear Street CFO Asbury to guide Canton Coin treasury build‑out - Stock Titan
Why Tharimmune Inc. stock remains a top recommendation2025 Market WrapUp & Free Real-Time Market Sentiment Alerts - Newser
How buybacks impact Tharimmune Inc. stock value2025 EndofYear Setup & Daily Risk Controlled Trade Plans - Newser
How Tharimmune Inc. stock reacts to Fed rate cutsPortfolio Gains Report & Consistent Income Trade Ideas - Newser
Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - The Holland Sentinel
Will Tharimmune Inc. stock benefit from infrastructure spendingInsider Buying & Technical Entry and Exit Tips - Newser
Is Tharimmune Inc. stock attractive for growth ETFsEarnings Recap Summary & High Return Stock Watch Alerts - Newser
Tharimmune (THAR) Stock Analysis Report | Financials & Insights - Benzinga
Can Tharimmune Inc. stock weather global recessionMarket Trend Report & AI Enhanced Trade Execution Alerts - BỘ NỘI VỤ
Reviewing Tharimmune (NASDAQ:THAR) and Ventyx Biosciences (NASDAQ:VTYX) - Defense World
Tharimmune Raises $545 Million in Private Placement to Acquire Canton Coin and Expand Blockchain Adoption - Global Legal Chronicle
What drives Tharimmune Inc stock priceSmall Cap Stock Opportunities & Build Capital Safely - earlytimes.in
Tharimmune Shares Jump After FDA Signals Support for TH104 Modeling Plan - MSN
Crypto Company Creates Bizarre Drug - Futurism
Tharimmune Stock Plummets -46% With 9-Day Losing Streak - Trefis
Using Bollinger Bands to evaluate Tharimmune Inc.Gap Up & Expert Curated Trade Setups - newser.com
Will Tharimmune Inc. stock benefit from sector rotationPortfolio Performance Report & Free Accurate Trade Setup Notifications - newser.com
Why analysts upgrade Tharimmune Inc. stockJuly 2025 Selloffs & Free Real-Time Volume Trigger Notifications - newser.com
How resilient is Tharimmune Inc. stock in market downturnsWatch List & Trade Opportunity Analysis Reports - newser.com
Is Tharimmune Inc. stock a buy for dividend growthTrade Exit Summary & Stepwise Swing Trade Plans - newser.com
What insider trading reveals about Tharimmune Inc. stock2025 Momentum Check & Safe Capital Growth Tips - newser.com
Is Tharimmune Inc. stock attractive for retirement portfoliosWeekly Gains Report & Capital Efficiency Focused Strategies - newser.com
Will Tharimmune Inc. stock deliver long term returnsInsider Selling & Verified Momentum Stock Alerts - newser.com
What the charts say about Tharimmune Inc. todayMarket Risk Report & Pattern Based Trade Signal System - newser.com
Will earnings trigger a reversal in Tharimmune Inc.July 2025 Sentiment & Expert Verified Movement Alerts - newser.com
Using data models to predict Tharimmune Inc. stock movementWeekly Investment Summary & Accurate Buy Signal Alerts - newser.com
Will Tharimmune Inc. stock sustain high P E ratiosWall Street Watch & High Accuracy Swing Entry Alerts - newser.com
Is Tharimmune Inc. still worth holding after the dip2025 Short Interest & Risk Adjusted Buy and Sell Alerts - newser.com
[Form 3] Tharimmune, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Tharimmune Shares Drop Premarket Following FDA Feedback on Plan for Lead Clinical Asset - MarketScreener
Tharimmune rises after US FDA backs opioid overdose prevention drug plan - TradingView
Tharimmune stock rises after FDA provides positive feedback on TH104 By Investing.com - Investing.com Nigeria
Tharimmune stock rises after FDA provides positive feedback on TH104 - Investing.com
Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids - Stock Titan
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):